Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
[RESULTS] Median follow-up was 77 months (Interquartile range [IQR] 37-133).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
While oncological outcomes are not equivalent to primary treatment, STF appears to be a feasible and reasonably safe option to extend local control in carefully selected candidates. Larger, prospective studies are needed before broader conclusions can be drawn.
OpenAlex 토픽 ·
Prostate Cancer Diagnosis and Treatment
Urinary Bladder and Prostate Research
Bladder and Urothelial Cancer Treatments
[OBJECTIVE] To report long-term oncologic and functional outcomes of a second therapeutic freeze (STF) after salvage cryoablation (sCryo) for biopsy-proven persistence following radiotherapy for local
- 95% CI 15.0-80.4
- 추적기간 77 months
APA
S. Balaji, Mahdi Mottaghi, et al. (2026). Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer.. The Prostate. https://doi.org/10.1002/pros.70181
MLA
S. Balaji, et al.. "Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer.." The Prostate, 2026.
PMID
41985090
Abstract
[OBJECTIVE] To report long-term oncologic and functional outcomes of a second therapeutic freeze (STF) after salvage cryoablation (sCryo) for biopsy-proven persistence following radiotherapy for localized prostate cancer.
[PATIENTS AND METHODS] We retrospectively reviewed 10 men with biopsy-proven local recurrence after sCryo following radiotherapy who underwent a STF. Outcomes were urinary and erectile function (social continence 0-1 pad/day; potency defined as International Index of Erectile Function-5 (IIEF-5) score ≥ 17), complications (Clavien-Dindo classification), and oncologic endpoints: failure-free survival (FFS), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS). FFS was defined as the absence of Phoenix biochemical failure, radiographic progression, initiation of systemic therapy, or prostate cancer-specific death. MFS, CSS, and OS were time-to-event endpoints, estimated using Kaplan-Meier methods.
[RESULTS] Median follow-up was 77 months (Interquartile range [IQR] 37-133). The median interval between the cryoablations was 22 months (IQR 10-33). At 5 years, FFS was 52.5% (95% CI 15.0-80.4), MFS was 80.0% (95% CI 40.9-94.6), CSS was 87.5% (95% CI 38.7-98.1), and OS was 75.0% (95% CI 31.5-93.1). Median ADT/systemic-therapy deferral after STF was 19 months (IQR 9-42.5). After STF, 7/10 men were socially continent; and 6/10 were pad-free at 1 year. Both men who were potent pre-STF, remained potent. No Clavien-Dindo ≥ III complications were attributable to STF, though a rectourethral fistula was observed at 5 months post-STF in a single patient.
[CONCLUSION] In this limited cohort with intermediate- to long-term follow-up, STF after prior sCryo preserved genitourinary function and deferred ADT in select men with local recurrence after radiation and sCryo. While oncological outcomes are not equivalent to primary treatment, STF appears to be a feasible and reasonably safe option to extend local control in carefully selected candidates. Larger, prospective studies are needed before broader conclusions can be drawn.
[PATIENTS AND METHODS] We retrospectively reviewed 10 men with biopsy-proven local recurrence after sCryo following radiotherapy who underwent a STF. Outcomes were urinary and erectile function (social continence 0-1 pad/day; potency defined as International Index of Erectile Function-5 (IIEF-5) score ≥ 17), complications (Clavien-Dindo classification), and oncologic endpoints: failure-free survival (FFS), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS). FFS was defined as the absence of Phoenix biochemical failure, radiographic progression, initiation of systemic therapy, or prostate cancer-specific death. MFS, CSS, and OS were time-to-event endpoints, estimated using Kaplan-Meier methods.
[RESULTS] Median follow-up was 77 months (Interquartile range [IQR] 37-133). The median interval between the cryoablations was 22 months (IQR 10-33). At 5 years, FFS was 52.5% (95% CI 15.0-80.4), MFS was 80.0% (95% CI 40.9-94.6), CSS was 87.5% (95% CI 38.7-98.1), and OS was 75.0% (95% CI 31.5-93.1). Median ADT/systemic-therapy deferral after STF was 19 months (IQR 9-42.5). After STF, 7/10 men were socially continent; and 6/10 were pad-free at 1 year. Both men who were potent pre-STF, remained potent. No Clavien-Dindo ≥ III complications were attributable to STF, though a rectourethral fistula was observed at 5 months post-STF in a single patient.
[CONCLUSION] In this limited cohort with intermediate- to long-term follow-up, STF after prior sCryo preserved genitourinary function and deferred ADT in select men with local recurrence after radiation and sCryo. While oncological outcomes are not equivalent to primary treatment, STF appears to be a feasible and reasonably safe option to extend local control in carefully selected candidates. Larger, prospective studies are needed before broader conclusions can be drawn.